AstraZeneca Aktie News

Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at Citi following full-year results and 2026 guidance that the bank described as “reassuring”, with a reiterated target price of £170 and unchanged earnings forecasts. Management confirmed expectations for low double-digit earnings growth in 2026, aligning wit...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming that prioritizes the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. During its fifth year, AstraZeneca's...

AstraZeneca PLC delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. AZN targets $80bn in revenues by 2030, driven by oncology, pipeline launches, and a $50bn US investment; management expresses increasing confidence. Patent expirations loom for key drugs, but pipeline assets and AI-driven innovation are expected to offset risks and ...

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript

AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3 EPS ($)...

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN)  full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust operational performance and a renewed commitment to long-term growth, analysts said. Fourth-quarter revenue came in at $15.5 billion, 2% ahead at constant exchange rates and just over 1% above consensus.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) delivered strong full-year results for 2025, driven by solid commercial performance across all major regions and sustained pipeline momentum, as the Anglo-Swedish pharmaceutical group continued what it called a “catalyst-rich period.” Total revenue for the year rose 8% at constant exchange rates to $58.7 billion, with product sales contributing $55.6 billio...